Notably, the combination of iRGD liposomes with anti-PD-L1 therapy (clone 10F.9G2) in PBS (100 μL) stopped tumor growth (Figure 7e) and increased the survival rate of mice from 70% to 90% over 70 days (Figure 7f). This evidence concerns the gene CD274 and neoplasm.